Oral erythromycin and the risk of sudden death from cardiac causes

New England Journal of Medicine

Volumn 351, Issue 11, 2004, Pages

  Ray, Wayne A ^a,b   Murray, Katherine T ^a   Meredith, Sarah ^a   Narasimhulu, Sukumar Suguna ^a   Hall, Kathi ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMOXICILLIN; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; DILTIAZEM; DISOPYRAMIDE; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NITROIMIDAZOLE DERIVATIVE; PIMOZIDE; PROCAINAMIDE; QUINIDINE; SOTALOL; TERFENADINE; TROLEANDOMYCIN; VERAPAMIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG USE; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK; SUDDEN DEATH;

ADMINISTRATION, ORAL; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CALCIUM CHANNEL BLOCKERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYTOCHROME P-450 CYP3A; DEATH, SUDDEN, CARDIAC; DILTIAZEM; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITROIMIDAZOLES; OXIDOREDUCTASES, N-DEMETHYLATING; RISK; TROLEANDOMYCIN; VERAPAMIL;

EID: 19244365446     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040582     Document Type: Article

References (45)

1. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1-18.
2. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA 1998; 280:1774-6.
3. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35:197-200.
4. Koh TW. Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol 2001;24:1575-6.
5. Vogt AW, Zollo RA. Long Q-T syndrome associated with oral erythromycin used in preoperative bowel preparation. Anesth Analg 1997;85:1011-3.
6. Tschida SJ, Guay DRP, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996;16:663-74.
7. Stanat SJC, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 2003;254:1-7.
8. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 2002;72: 524-35.
9. Goldschmidt N, Azaz-Livshits T, Gotsman I, Nir-Paz R, Ben-Yehuda A, Muszkat M. Compound cardiac toxicity of oral erythromycin and verapamil. Ann Pharmacother 2001;35:1396-9.
10. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989;129:837-49.
11. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-7.
12. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-41.
13. Piper JM, Ray WA, Griffin MR, Fought R, Daugherty JR, Mitchel E Jr. Methodological issues in evaluating expanded Medicaid coverage for pregnant women. Am J Epidemiol 1990;132:561-71.
14. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev 1990;12:87-107.
15. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142:1103-12.
16. Landry JA, Smyer MA, Tubman JG, Lago DJ, Simonson W. Validation of two methods of data collection of self-reported medicine use among the elderly. Gerontologist 1988; 28:672-6.
17. Leister KA, Edwards WA, Christensen DB, Clark H. A comparison of patient drug regimens as viewed by the physician, pharmacist and patient. Med Care 1981;24:658-64.
18. Johnson RE, Vollmer WM. Comparing sources of drug data about the elderly. J Am Geriatr Soc 1991;39:1079-84.
19. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
20. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348-54.
21. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997; 51:415-9.
22. Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 1998;63: 640-5.
23. Warot D, Bergougnan L, Lamiable D, et al. Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987;32:389-93.
24. Varis T, Backman JT, Kivisto KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000;67:215-21.
25. Abernethy DR, Barbey JT, Franc J, et al. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 2001;69:96-103.
26. Kirch W, Janisch HD, Ohnhaus EE, van Peer A. Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit 1989;11:411-4.
27. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 2003;43:1274-82.
28. Simard C, O'Hara GE, Prevost J, Guilbaud R, Massee R, Turgeon J. Study of the drug-drug interaction between simvastatin and cisapride in man. Eur J Clin Pharmacol 2001;57:229-34.
29. Nicolau DP, Uber WE, Crumbley AJ III, Strange C. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant 1992;11:564-8.
30. Marcus FI, Cobb LA, Edwards JE, et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol 1988;61:8-15.
31. Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982; 65:457-64.
32. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-7.
33. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23-8.
34. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health 1992; 82:243-8.
35. Rawson NSB, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-43.
36. Wiseman LR, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-52.
37. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
38. Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol 2001;51:133-42.
39. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998;64:355-62.
40. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998;285:428-37.
41. Murray KT, Roden DM. Disorders of cardiac repolarization: the long QT syndromes. In: Crawford MH, DiMarco JO, Paulus WJ, eds. Cardiology. St. Louis: Mosby, 2004:765-74.
42. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999;48:829-38.
43. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-41.
44. Gil M, Sala M, Anguera I, et al. QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003;92:995-7.
45. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993;95:431-8.